Anti-inflammatory effects of combined treatment with acetyl salicylic acid and atorvastatin in haemodialysis patients affected by Normal Weight Obese syndrome

Pharmacological Research

Volumn 57, Issue 2, 2008, Pages 93-99

  Di Renzo, Laura ^a,b   Noce, Annalisa ^c   De Angelis, Sandro ^a   Miani, Natascia ^c   Di Daniele, Nicola ^c   Tozzo, Carmela ^c   De Lorenzo, Antonino ^a,b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b INDiM   (Italy)

^c TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

Author keywords

Body composition; DXA; ESRD; Inflammation; NWO syndrome; PINI

Indexed keywords

ACETYLSALICYLIC ACID; ALBUMIN; ATORVASTATIN; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; OROSOMUCOID; PREALBUMIN;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ANTHROPOMETRY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BODY COMPOSITION; CHOLESTEROL BLOOD LEVEL; CHRONIC INFLAMMATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HEMODIALYSIS PATIENT; HUMAN; INCIDENCE; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; NORMAL WEIGHT OBESE SYNDROME; NUTRITIONAL ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SYNDROME;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICHOLESTEREMIC AGENTS; ASPIRIN; BODY FAT DISTRIBUTION; BODY MASS INDEX; BODY WEIGHT; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; DRUG THERAPY, COMBINATION; FEMALE; HEPTANOIC ACIDS; HUMANS; INFLAMMATION; KIDNEY FAILURE, CHRONIC; LIPID METABOLISM; MALE; MIDDLE AGED; NUTRITION ASSESSMENT; OBESITY; PREALBUMIN; PYRROLES; RENAL DIALYSIS; SERUM ALBUMIN; SYNDROME;

EID: 40149087164     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2007.11.005     Document Type: Article

References (37)

1. Cheung A.K., Sarnak M.J., Yan G., Dwyer J.T., Heyka R.J., Rocco M.V., et al. Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int 58 (2000) 353-362
2. Sarnak M.J., and Levey A.S. Cardiovascular disease and chronic renal disease: a new paradigm. Am J Kidney Dis 35 (2000) S117-S131
3. Foley R.N., Parfery P.S., and Sarnak M.J. Clinical epidemiology of cardiovascular disease. Am J Kidney Dis 32 (1998) S112-S119
4. Stenvinkel P., Heimburger O., and Paultre F. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 55 (1999) 1899-1911 10.1046/j.1523-1755.1999.00422
5. Robless P., Mikhailidis D.P., and Stansby G. Systematic review of antiplatelet therapy for the prevention of myocardial infarction, stroke or vascular death in patients with peripheral vascular disease. Br J Surg 88 (2001) 787-800 10.1046/j.0007-1323.2001.01774
6. Youssef F., Gupta P., Seifalian A.M., Myint F., Mikhailidis D.P., and Hamilton G. The effect of short-term treatment with simvastatin on renal function in patients with peripheral arterial disease. Angiology 55 (2004) 53-62
7. Mann J.F., Gerstein H.C., and Pogue J. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Int Med 134 (2001) 629-636
8. Kershaw E.E., and Flier J.S. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 89 (2004) 2548-2556
9. Henrichot E., Juge-Aubry C.E., Pernin A., Pache J.C., Velebit V., Dayer J.M., et al. Production of chemokines by perivascular adipose tissue: a role in the pathogenesis of atherosclerosis?. Arterioscler Thromb Vasc Biol 25 (2005) 2594-2599 10.1161/01.ATV.0000188508.40052.35
10. Chen H. Cellular inflammatory response: novel insight for obesity and insulin resistance. Pharmacol Res 53 (2006) 469-477 10.1016/j.phrs.2006.03.003
11. De Lorenzo A., Martinoli R., Vaia F., and Di Renzo L. Normal Weight Obese (NWO) Women: an evaluation of candidate new syndrome. Nutr Metab Cardiovasc Dis 16 (2006) 513-523 10.1016/j.numecd.2005.10.010
12. De Lorenzo A., Del Gobbo V., Premrov M.G., Bigioni M., Galvano F., and Di Renzo L. Normal Weight Obese Syndrome: early inflammation?. Am J Clin Nutr 85 (2007) 40-45
13. Lam K.S., Cheng I.K., Janus E.D., and Pang R.W. Cholesterol-lowering therapy may retard the progression of diabetic nephropaty. Diabetologia 38 (1995) 604-609
14. Youssef F. The early effect of lipid-lowering treatment on carotid and femoral intima media thickness (IMT). Eur J Vasc Endovasc Surg 23 (2002) 358-364 10.1053/ejvs.2002.1611
15. Ingenbleek Y., and Carpentier Y.A. A prognostic inflammatory and nutritional index scoring critically ill patients. Int J Vitam Nutr Res 55 1 (1985) 91-101
16. Bonnefoy M., Ayzac L., Ingenbleek Y., Kostka T., Boisson R.C., and Bienvenu J. Usefulness of the prognostic inflammatory and nutritional index (PINI) in hospitalized elderly patients. Int J Vitam Nutr Res 68 (1998) 189-195
17. Diet, nutrition and the prevention of chronic diseases, Word Health Organ Tech Repor Ser 2003; 916: 1-149.
18. Lohman T.G., Roche A.F., and Martorell R. Anthropometric standardization reference manual. Human kinetics (1998), Champaing
19. De Lorenzo A., Andreoli A., and Candeloro N. Within-subject variability in body composition using dual-energy X-ray absorptiometry. Clin Physiol 17 (1997) 383-384
20. Al Suwaidi J., Higano S.T., Holmes Jr. D.R., Lennon R., and Lerman A. Obesity is independently associated with coronary endothelial dysfunction in patients with normal or mildly diseased coronary arteries. J Am Coll Cardiol 37 (2001) 1523-1528 10.1016/S0735-1097(01)01212-8
21. Zimmermann J., Herrlinger S., Pruy A., Metzger T., and Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 55 (1999) 648-658 10.1046/j.1523-1755.1999.00273
22. Bergstrom J., and Lindholm B. Malnutrition, cardiac disease, and mortality: an integrated point of view. Am J Kidney Dis 32 (1998) 834-841
23. Stenvinkel P. The role of inflammation in the anaemia of end-stage renal disease. Nephrol Dial Transpl 16 Suppl 7 (2001) 36-40
24. Kaysen G.A., Dubin J.A., Müller H.G., Mitch W.E., Rosales L.M., and Levin N.W. Relationships among inflammation nutrition and physiologic mechanisms establishing albumin levels in hemodialysis patients. Kidney Int 61 (2002) 2240-2249 10.1046/j.1523-1755.2002.00076
25. Kaysen G.A., Dubin J.A., Müller H.G., Mitch W.E., Levin N.W., and Group H.E.M.O. Levels of α1 acid glycoprotein and ceruloplasmin predict future albumin levels in hemodialysis patients. Kidney Int 60 (2001) 2360-2366 10.1046/j.1523-1755.2001.00052
26. Chagnac A., Weinstein T., Korzets A., Ramadan E., Hirsch J., and Gafter U. Glomerular hemodynamics in severe obesity. Am J Physiol Renal Physiol 278 (2000) F817-F822
27. Hsu C.Y., McCulloch C.E., Iribarren C., Darbinian J., and Go A.S. Body mass index and risk for end-stage renal disease. Ann Int Med 144 (2006) 21-28
28. Kalantar-Zadeh K., Kopple J.D., Kilpatrick R.D., McAllister C.J., Shinaberger C.S., Gjertson D.W., et al. Association of morbid obesity and weight change over time with cardiovascular survival in hemodialysis population. Am J Kidney Dis 46 (2005) 489-500 10.1053/j.ajkd.2005.05.020
29. Kalantar-Zadeh K. Recent advances in understanding the malnutrition-inflammation-cachexia syndrome in chronic kidney disease patients: what is next?. Semin Dial 18 (2005) 365-369 10.1111/j.1525-139X.2005.00074
30. Di Renzo L., Del Gobbo V., Bigioni M., Premrov M.G., Cianci R., and De Lorenzo A. Body composition analyses in normal weight obese women. Eur Rev Med Pharmacol Sci 10 (2006) 191-196
31. Di Renzo L., Bigioni M., Bottini F.G., Del Gobbo V., Premrov M.G., Cianci R., et al. Normal Weight Obese syndrome: role of single nucleotide polymorphism of IL-1 5Ralpha and MTHFR 677C T genes in the relationship between body composition and resting metabolic rate. Eur Rev Med Pharmacol Sci 10 (2006) 235-245
32. Di Renzo L., Bigioni M., Del Gobbo V., Premrov M.G., Barbini U., Di Lorenzo N., et al. Interleukin-1 (IL-1) receptor antagonist gene polymorphism in normal weight obese syndrome: relationship to body composition and IL-1 alpha and beta plasma levels. Pharmacol Res 55 (2007) 131-138 10.1016/j.phrs.2006.11.002
33. Miller L.M., Hopman W.M., Garland J.S., Yeates K.E., and Pilkey R.M. Cardioprotective medication use in hemodialysis patients. Can J Cardiol 22 (2006) 755-760
34. Mason N.A., Bailie G.R., Satayathum S., Bragg-Gresham J.L., Akiba T., Akizawa T., et al. HMG-coenzyme a reductase inhibitor use is associated with mortality reduction in hemodialysis patients. Am J Kidney Dis 45 (2005) 119-126 10.1053/j.ajkd.2004.09.025
35. Laufs U., La Fata V., Plutzky J., and Liao J.K. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 97 (1998) 1129-1135
36. Grandaliano G., Biswas P., Choudurry G.G., and Abboud H.E. Simvastatin inhibits PDGF-induced DNA synthesis in human glomerular mesangial cells. Kidney Int 44 (1993) 503-508
37. McCullough P.A., Sandberg K.R., Borzak S., Hudson M.P., Garg M., and Manley H.J. Benefits of aspirin and beta-blockade after myocardial infarction in patients with chronic kidney disease. Am Heart J 144 (2002) 206-207 10.1067/mhj.2002.125513